DHEA: Why, When, and How Much? Based on the Conference by Bruno Allolio (Wuerzburg), 50th International Clinical Endocrinology Days Henri-Pierre Klotz, September 2007

The document discusses the potential benefits of dehydroepiandrosterone (DHEA) supplementation in individuals with adrenal insufficiency, where DHEA levels are extremely low. Clinical studies have shown that DHEA supplementation can restore adrenal androgen levels, leading to improvements in neuropsychological evaluation scores, depression, anxiety, sexual interest, and satisfaction in patients. In women with hypopituitarism, DHEA has been noted to positively affect libido and may reduce the required doses of growth hormone (GH) replacement. Metabolically, DHEA may decrease total cholesterol and HDL cholesterol levels, but further research is needed to clarify its effects on insulin sensitivity, bone mineralization, and cardiovascular outcomes. DHEA treatment can be considered for adrenal insufficiency, particularly when patients' quality of life is not improved by adequate hormonal replacement therapy. The initial treatment dose is 25 mg/day, with a minimum treatment duration of six months, and can be increased to 50 mg/day if therapeutic goals are not met. Side effects include signs of hyperandrogenism such as hirsutism, seborrhea, acne, and alopecia. The document concludes that while DHEA may improve the quality of life and certain neuropsychological functions, and sexual satisfaction in women, more long-term studies are needed to determine the efficacy and safety of this therapeutic strategy. It also suggests that the benefits of DHEA may differ between sexes, necessitating separate studies for men and women.